StockMarketWire.com - The Vedanta Biosciences arm of biopharma company PureTech announced that preliminary results from its Phase 1a/1b clinical study of its live biotherapeutic product VE303 demonstrated safety, tolerability and proof of mechanism.

The product, a treatment candidate for recurrent Clostridium difficile infection, was expected to undergo a Phase 2 study before the end of the year.

"This rational development of proprietary microbiome-based drugs is the hallmark of Vedanta's pipeline, which is expected to include three additional clinical-stage product candidates in inflammatory bowel disease (in partnership with Janssen), food allergy, and cancer immunotherapy within the next nine months," said Joseph Bolen, Chief Scientific Officer at PureTech Health.


At 9:43am: [LON:PRTC] PureTech Health Plc share price was -0.75p at 164p



Story provided by StockMarketWire.com